Blood marker study for new stage IV colon cancer
Part of Cancer, Digestive system clinical trials.
This study looks at blood tests (inflammatory markers and small RNA molecules called microRNAs) to better predict how stage IV colon cancer may progress. It may help doctors identify who is likely to do better or worse and tailor future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with stage IV colorectal (colon/rectum) cancer
- You have not started any cancer treatment yet
- You are 18 years or older
- For control comparison: you do not have any cancer diagnosis
- You do not have illnesses or medicines that could change inflammation or immune levels (for example, inflammatory bowel disease or active autoimmune disease)
- You have not used corticosteroids or immunosuppressing medicines recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new blood test that may help doctors better understand how far colon cancer has spread. By testing a sample of your blood (taken before surgery), researchers hope to find patterns that predict the stage of cancer and help guide treatment decisions.
This study compares different blood tests to find the best way to detect tiny bits of cancer DNA after surgery for stage III colorectal cancer. It aims to help doctors decide if additional chemotherapy is needed to prevent the cancer from coming back.
This study looks at special tiny cell-signal particles (called exosomes) and related pathways to understand colorectal cancer. Your results from samples may help researchers learn how these signals relate to the disease after surgery.
This study tracks DNA fragments in your blood before, during, and after treatment for stage III colon cancer. It aims to see if these 'ctDNA' and 'TEP' levels can predict how well your tumor responds to neoadjuvant therapy (treatment before surgery).
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
This study looks for early signs that treatment is not working in people with stage IV colon or rectal cancer that has spread only to the liver. It may help doctors adjust care sooner by using regular blood, stool, and tissue samples around liver procedures.
Hear when a new Colorectal Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.